Trial Profile
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients. Prospective Phase III Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2018 Status changed from recruiting to completed.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting.
- 25 Nov 2016 New trial record